trending Market Intelligence /marketintelligence/en/news-insights/trending/2LqL0qNeprkcJ_Q7FpUoHw2 content esgSubNav
In This List

US FDA accepts application for Allergan's potential acne treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA accepts application for Allergan's potential acne treatment

The U.S. Food and Drug Administration accepted Allergan plc and Paratek Pharmaceuticals Inc.'s new drug application for Seysara to treat moderate to severe acne vulgaris in patients aged 9 years or more.

The application includes two phase 3 studies evaluating Seysara, both of which had met their primary endpoints.

The company is expecting a potential U.S. approval for Seysara in the second half of 2018, said David Nicholson, Allergan's chief research and development officer.

Allergan has U.S. rights to the development and commercialization of Seysara, while Paratek retains all ex-U.S. rights.